Healthcare Stocks and Market Cycles: Amgen, Bristol-Myers, CVS and J&J vs XLV and the S&P 500

The healthcare sector fund XLV has a slow 7.8-year cycle. We compare Amgen, Bristol-Myers Squibb, CVS, Johnson & Johnson and Vertex with XLV and SPY through every major drawdown.

Healthcare stocks are usually filed under defensive investments: people need medicines and treatment in any economy. But the sector also has its own rhythms, driven by drug patents, product pipelines, regulation and the periodic rotation of investors into and out of safety. We measured the multi-year cycles of 26 long-history healthcare stocks and compared them with the Health Care Select Sector SPDR fund (XLV) and with SPY.

  • XLV is one of the few sector funds with a measurable cycle: a slow 7.8-year wave with about a 4% chance of luck.
  • Amgen, Bristol-Myers Squibb, CVS Health, Johnson & Johnson and Vertex show multi-year cycles of 4.5–7.6 years.
  • Healthcare protected investors in crashes: XLV fell 37% in 2007–09 against SPY’s 52% and 14% in 2022 against 25%.
  • But the sector has drawdowns of its own: from August 2024 to July 2025 XLV fell 17% while SPY rose 12%.
  • The deepest single-stock declines were pipeline and patent stories: Bristol-Myers Squibb fell 49% in 2022–24 while XLV was flat and SPY rose 29%.

Why healthcare stocks move in cycles

Two forces overlap. The first is defensive rotation: like consumer staples, healthcare gains favour when growth slows and loses it in speculative bull markets. The second is the product cycle of drug makers and biotechnology companies: a blockbuster drug drives years of earnings growth, then patent expiration brings generic competition, and the stock waits for the next generation of products. Policy debates over drug pricing and insurance add sector-wide swings every few years.

Five healthcare stocks against XLV and SPY

The chart shows each stock’s swings around its own long-term trend; switch XLV and SPY on and off in the legend.

Healthcare stocks: multi-year cycle statistics, with the Health Care Select Sector SPDR (XLV) and SPY. "Chance it's luck" = share of random-walk simulations producing a cycle at least as strong; correlations compare the swings around each symbol's long-term trend.
SymbolNameComplete yearsStrongest cycleChance it's luckCycle ratingSwing around trendTypical peak spacingDeclines during S&P sell-offsMoves with XLVMoves with SPY
AMGNAmgen Inc424.5 yrs2%Moderate±24%3.9 yrs3 of 70.370.37
BMYBristol-Myers Squibb Company537.6 yrs2%Moderate±12%3.5 yrs9 of 130.400.57
CVSCVS Health Corporation537.3 yrs2%Moderate±18%2.3 yrs10 of 190.540.58
JNJJohnson & Johnson564.9 yrs4%Moderate±9%2.9 yrs9 of 150.420.35
VRTXVertex Pharmaceuticals Inc344.6 yrs5%Moderate±27%1.1 yrs7 of 140.220.31
LLYEli Lilly and Company538.0 yrs12%Weak±10%4.0 yrs8 of 100.460.45
MRKMerck & Co Inc535.3 yrs17%None±10%3.4 yrs8 of 130.440.44
PFEPfizer Inc537.2 yrs28%None±9%2.7 yrs10 of 160.510.54
UNHUnitedHealth Group Inc415.2 yrs19%None±18%1.8 yrs5 of 110.500.18
ABTAbbott Laboratories535.4 yrs31%None±7%3.3 yrs8 of 150.360.42
GILDGilead Sciences Inc335.9 yrs11%Weak±15%1.5 yrs6 of 110.470.20

Biotechnology names have the largest swings: Amgen ±24% and Vertex ±27% around trend, with correlations to XLV of only 0.37 and 0.22, because their fortunes depend on individual drugs. The large pharmaceutical companies and insurers sit in between: Bristol-Myers Squibb (7.6 years, ±12%), CVS Health (7.3 years, ±18%) and Johnson & Johnson (4.9 years, ±9%). Eli Lilly, Merck and Pfizer show no reliable period.

Spotlight: XLV, the healthcare sector cycle

The healthcare sector fund has a slow, fairly regular cycle: peaks a median 2.8 years apart on shorter swings, riding a 7.8-year wave of about ±6% around trend. Its turning points are more regularly spaced than most funds’.

Lining up XLV’s drawdowns with SPY shows both sides of a defensive sector. In market-wide sell-offs (2002, 2007–09, 2011, 2020, 2022) healthcare usually fell less than the S&P 500. But its own corrections, in 2010, 2015 and especially 2024–25, came while the broad market was flat or rising.

XLV: major declines (monthly closes, reversals of 12% or more), latest first, with other symbols over the same months. "–" = no data for that period.
Peak – troughMonthsXLVSPY same monthsXLV recovery to next peakDuring S&P sell-off
Aug 2024 – Jul 202511−17%+12%+45% (so far)Yes
Dec 2021 – Sep 20229−14%−25%+30%Yes
Dec 2019 – Mar 20203−13%−20%+59%Yes
Jul 2015 – Sep 20152−14%−9%+54%No
May 2011 – Sep 20114−12%−16%+141%Yes
Mar 2010 – Aug 20105−13%−10%+29%No
May 2007 – Feb 200921−37%−52%+40%Yes
May 2002 – Sep 20024−15%−24%+45%Yes

Bristol-Myers Squibb and Amgen: product cycles

Bristol-Myers Squibb has a 7.6-year cycle and a history of long, company-specific drawdowns. It lost 70% from December 2000 to March 2003 while XLV slipped only 2%, and 49% from November 2022 to May 2024 while XLV gained 3% and SPY 29%, as investors weighed the patent expirations of its largest drugs. Amgen shows the same pattern: a 48% fall in 2005–08 while XLV and SPY were roughly flat, followed by a gain of more than 1,000% to its latest peak.

BMY: major declines (monthly closes, reversals of 19% or more), latest first, with other symbols over the same months. "–" = no data for that period.
Peak – troughMonthsBMYXLV same monthsSPY same monthsBMY recovery to next peakDuring S&P sell-off
Mar 2025 – Jul 20254−29%−11%+13%+46% (so far)Yes
Nov 2022 – May 202418−49%+3%+29%+48%Yes
Jul 2021 – Nov 20214−21%−2%+4%+50%Yes
Feb 2018 – Jul 201917−33%+8%+9%+53%Yes
Jul 2016 – Jan 20176−34%−6%+5%+35%No
Jun 2007 – Feb 200920−42%−35%−51%+306%Yes
Dec 2003 – Oct 200522−26%+1%+8%+49%No
Dec 2000 – Mar 200327−70%−2%−35%+35%Yes
AMGN: major declines (monthly closes, reversals of 27% or more), latest first, with other symbols over the same months. "–" = no data for that period.
Peak – troughMonthsAMGNXLV same monthsSPY same monthsAMGN recovery to next peakDuring S&P sell-off
Nov 2005 – Mar 200828−48%+1%+5%+1,015% (so far)Yes
Aug 2000 – Sep 200225−45%−16%−46%+94%Yes
May 1997 – Sep 19974−28%–+11%+533%No
Nov 1992 – Jul 19938−54%––+282%No
May 1987 – Nov 19876−48%––+2,080%Yes

What this means for investors

  • The sector fund is defensive; single stocks are not. XLV’s drawdowns have mostly been 12–17%, while individual drug makers have halved on product news.
  • Healthcare has its own corrections, often driven by policy and pricing debates, that can occur while the market rises (as in 2024–25).
  • Patent and pipeline cycles matter more than the business cycle for pharmaceutical and biotechnology stocks.
  • Long waves. At about 7–8 years, the sector’s cycle requires patience.

How we measure a cycle: each symbol’s monthly closes are compared with their own long-term trend (a 10-year local regression of the log price). We then test every cycle length from 2 to 8 years and ask how often random price wandering with the same persistence produces a cycle at least as strong (120 simulations per symbol; this is the “chance it’s luck” column). Turning points are peaks and troughs separated by a reversal scaled to each symbol’s volatility. Prices exclude dividends. Full method in our guide to stock market cycles.

Frequently asked questions

Are healthcare stocks defensive?

As a sector, yes: XLV fell 37% in 2007–09 against SPY’s 52% and 14% in 2022 against 25%. Individual pharmaceutical and biotechnology stocks are much less defensive, because their prices depend on specific drugs, patents and trial results.

Do healthcare stocks have a cycle?

The healthcare sector fund XLV shows a slow 7.8-year cycle with about a 4% chance of luck, one of the few sector funds with a measurable cycle. Amgen, Bristol-Myers Squibb, CVS Health, Johnson & Johnson and Vertex show cycles of 4.5–7.6 years.

Why do pharmaceutical stocks fall when the market rises?

Mostly because of product cycles: when a blockbuster drug approaches patent expiration, investors price in falling sales until new drugs replace it. Bristol-Myers Squibb fell 49% in 2022–24 while SPY rose 29%. Drug-pricing policy debates can also hit the whole sector.

What is the healthcare ETF XLV?

The Health Care Select Sector SPDR Fund (XLV) holds the healthcare companies in the S&P 500, including drug makers, medical-device companies, insurers and biotechnology firms. It is the benchmark we compare against here; this is not a recommendation.

Are biotech stocks more volatile than pharma stocks?

Generally yes. In our data Amgen swings about ±24% and Vertex about ±27% around their long-term trends, compared with about ±9–12% for Johnson & Johnson and Bristol-Myers Squibb.

More market-cycle research

Figures are historical, based on monthly closing prices to mid-November 2026, and are updated as new data arrives. Past cycles do not predict future returns; this is research, not investment advice.